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Abstract
Background: Previous meta-analyses of published and unpublished trials indicate that antidepressants provide modest
benefits compared to placebo in the treatment of depression; some have argued that these benefits are not clinically
significant. However, these meta-analyses were based only on trials submitted for the initial FDA approval of the medication
and were limited to those aimed at treating depression. Here, for the first time, we assess the efficacy of a selective
serotonin reuptake inhibitor (SSRI) in the treatment of both anxiety and depression, using a complete data set of all
published and unpublished trials sponsored by the manufacturer.
Methods and Findings: GlaxoSmithKline has been required to post the results for all sponsored clinical trials online,
providing an opportunity to assess the efficacy of an SSRI (paroxetine) with a complete data set of all trials conducted. We
examined the data from all placebo-controlled, double-blind trials of paroxetine that included change scores on the
Hamilton Rating Scale for Anxiety (HRSA) and/or the Hamilton Rating Scale for Depression (HRSD). For the treatment of
anxiety (k=12), the efficacy difference between paroxetine and placebo was modest (d=0.27), and independent of baseline
severity of anxiety. Overall change in placebo-treated individuals replicated 79% of the magnitude of paroxetine response.
Efficacy was superior for the treatment of panic disorder (d=0.36) than for generalized anxiety disorder (d=0.20). Published
trials showed significantly larger drug-placebo differences than unpublished trials (d’s=0.32 and 0.17, respectively). In
depression trials (k=27), the benefit of paroxetine over placebo was consistent with previous meta-analyses of
antidepressant efficacy (d=0.32).
Conclusions: The available empirical evidence indicates that paroxetine provides only a modest advantage over placebo in
treatment of anxiety and depression. Treatment implications are discussed.
Citation: Sugarman MA, Loree AM, Baltes BB, Grekin ER, Kirsch I (2014) The Efficacy of Paroxetine and Placebo in Treating Anxiety and Depression: A Meta-
Analysis of Change on the Hamilton Rating Scales. PLoS ONE 9(8): e106337. doi:10.1371/journal.pone.0106337
Editor: Brett Thombs, McGill University, Canada
Received February 18, 2014; Accepted August 4, 2014; Published August 27, 2014
Copyright:  2014 Sugarman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The current study did not have any funding sources. Study design, data collection and analysis, decision to publish, and preparation of the manuscript
were all done at the discretion of the study authors.
Competing Interests: The authors have declared that no competing interests exist.
* Email: Mike.Sugarman@wayne.edu
Introduction
Antidepressant medications are prescribed to 8.7% of the US
population, making them the third most common class of
prescription medications [1]. Antidepressants are approved for
the treatment of depression and several other mental disorders,
including generalized anxiety disorder [2], panic disorder, social
anxiety disorder, obsessive-compulsive disorder, and post-trau-
matic stress disorder [3]. While several meta-analytic investiga-
tions have been conducted examining the efficacy of antidepres-
sants in the treatment of depression, fewer analyses have focused
on the efficacy of these drugs in the treatment of other conditions,
including anxiety disorders. Moreover, most meta-analyses are
conducted only using published studies. However, approximately
40% of the antidepressant trials conducted by pharmaceutical
companies are not published [4,5]. Therefore, meta-analyses of
antidepressant trials are prone to overestimations of effectiveness
due to publication bias.
One strategy for avoiding publication bias is to conduct meta-
analyses on data submitted to the Food and Drug Administration
(FDA) in the process of obtaining drug approval, as the FDA
requires that pharmaceutical companies provide information on
all of the trials that they have sponsored [6]. However, analyses of
data submitted to the FDA [5,7–9] only include trials conducted
prior to approval of the medications. Pharmaceutical companies
often conduct additional placebo-controlled double-blind trials
after the medications have been approved. Thus, the data
submitted to the FDA do not represent the most complete datasets
of studies conducted with the medications.
The current study addresses these potential biases by evaluating
the efficacy of paroxetine, a selective serotonin reuptake inhibitor
(SSRI), across all placebo-controlled double-blind studies con-
ducted by its manufacturer, GlaxoSmithKline, including those
conducted following FDA approval. As part of a 2004 lawsuit
settlement, GlaxoSmithKline has been required to post online the
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Register [10,11]. Thus, unlike most other antidepressants, all
studies of paroxetine can be evaluated without fear of publication
bias. A recent meta-analysis reported that paroxetine did not
significantly differ in overall efficacy from citalopram, escitalo-
pram, fluoxetine, or sertraline in the treatment of depression [12].
Therefore, findings concerning the efficacy of paroxetine in the
treatment of anxiety disorders could possibly generalize to other
SSRIs, although further research would be necessary to support
that proposition.
The current analysis is the first to evaluate the efficacy of an
SSRI in the treatment of anxiety disorders using a complete
dataset of sponsored placebo-controlled trials. Paroxetine and
other SSRIs have been approved for the treatment of a variety of
anxiety disorders, including generalized anxiety disorder, panic
disorder, and social anxiety disorder [13–24]. To date, however,
only two meta-analyses have investigated the degree to which
SSRIs reduce symptoms of anxiety, and both of these meta-
analyses focused exclusively on panic disorder [25,26]. One of
these studies [25] found a moderate advantage for antidepressants
compared to placebo (Hedge’s g=0.41), and the other study [26]
suggested that antidepressants provide a somewhat larger benefit
(Mean Effect Size=0.55). Notably, no meta-analyses have
examined anxiety disorders other than panic disorder and none
have examined whether SSRIs are differentially effective in
treating different types of anxiety disorders. Further, both of these
meta-analyses [25,26] observed evidence for publication bias in
their analyses and did not have access to a full database of
published and unpublished trials, indicating that these figures may
be an overestimate of the true effect sizes. The availability of the
GlaxoSmithKline Clinical Trial Register provides an opportunity
to evaluate the efficacy of an SSRI in the treatment of anxiety
disorders without a concern for publication bias.
The availability of a complete dataset of pre-marketing and
post-marketing trials also allows for the further examination of
antidepressant efficacy in the treatment of depression. Previous
meta-analyses of antidepressant data obtained from the FDA have
consistently revealed modest differences between drug and
placebo, with mean effect sizes ranging from d=0.31 to 0.32
[5,7], and raw score differences in improvement on the Hamilton
Rating Scale for Depression (HRSD) [27] ranging from 1.80 to
2.51 points [7,28]. The overall magnitude of the change in
placebo-treated individuals duplicated greater than 80% of the
antidepressant response [7]. The current study further evaluates
the magnitude of benefit between an SSRI medication and
placebo in the treatment of depression using the database of trials
available through the GlaxoSmithKline Clinical Trial Register.
The goals of the current study are two-fold: 1) to determine the
magnitude of benefit for paroxetine compared to placebo in the
treatment of anxiety, and 2) to determine the magnitude of benefit
for paroxetine compared to placebo in the treatment of
depression, utilizing access to a complete database of clinical trials
sponsored by the manufacturer. Studies examining antidepressant
efficacy in the treatment of anxiety disorders have used a wide
range of outcome measures. However, a commonly used measure
across double-blind trials of anxiety disorders including general-
ized anxiety disorder and panic disorder is the Hamilton Rating
Scale for Anxiety (HRSA) [29]. Therefore, the current study will
focus on the HRSA as an indicator of anxiety-related outcomes.
For both HRSA and HRSD analyses, we will analyze available
moderator variables to determine which trial variables influence
effect sizes in drug and placebo groups.
Methods
Study Retrieval
Data for all trials were obtained through the GlaxoSmithKline
Clinical Trial Register [30]. According to the terms of the 2004
lawsuit, this database is required to contain every trial sponsored
by GlaxoSmithKline on their medications, including paroxetine.
Thus, we do not have concerns of publication bias or selective
access to studies. The ‘‘result summary’’ files were downloaded
from the website in March 2013. A total of 371 result summaries
of studies on paroxetine were downloaded. Each study was
evaluated for appropriateness in the current analyses. Trials were
included in the current study if they met the following criteria: 1)
they were a double-blind randomized intervention study contain-
ing a placebo group and at least one group receiving paroxetine; 2)
they were conducted within an indicated clinical population with
DSM-III or DSM-IV (depending on when the study was
conducted) diagnoses of mood and/or anxiety disorders and not
on healthy volunteers; 3) they included change on the HRSA and/
or the HRSD from pre-treatment to post-treatment amongst their
outcome measures; 4) the outcome indices were appropriately
matched to the clinical diagnosis (i.e., the HRSA was evaluated in
individuals with diagnoses of anxiety disorders and the HRSD was
evaluated in individuals with depression); and 5) they did not
include individuals who had systematically received additional
treatment prior to the randomization to placebo/paroxetine.
Examples meeting this last exclusion criterion include trials in
which all participants were previously stabilized on another
treatment and trials in which all participants simultaneously
received treatment in addition to paroxetine.
Additionally, we obtained information regarding the initial
approval of paroxetine from the FDA in accordance with the
Freedom of Information Act [31]. This initial submission included
16 trials examining the efficacy of paroxetine in the treatment of
depression and utilized the HRSD as an outcome measure. These
trials have been included in previous meta-analyses of antidepres-
sant data submitted to the FDA [7,8]. We matched these 16 trials
to their respective result summary file obtained through the GSK
Clinical Trial Register. However, we observed discrepancies in
sample sizes for 11 of the 16 studies (ranging from n=1ton=12
for each group) between the data obtained the FDA and data from
the GSK Clinical Trial Register result summaries. In all of these
cases, samples were larger in the FDA datasets than in those
obtained from the GSK Clinical Trial Register. In the interests of
using the most complete datasets and presenting results consistent
with previous meta-analyses including these trials, we used the
data obtained from the FDA for these 11 trials in our analyses.
Further examination revealed that the differences in sample sizes
in these trials did not contribute to substantial differences in trial
outcome. The overall weighted meta-analytic pre-post effect sizes
for both paroxetine and placebo-treated individuals across all trials
were essentially identical (within d=0.002) when comparing the
two data sources.
Meta-Analytic Data Synthesis
For each outcome index (HRSA and HRSD), we conducted
two types of data analysis: 1) an analysis of each trial’s arithmetic
means for both groups to determine the overall meta-analytic
‘‘effect size’’ [32] as a comparison between the two groups (i.e., the
effect size difference between paroxetine and placebo), and 2) each
group’s change was calculated as the standardized mean
difference, dividing the change score by the standard deviation
of the change [33]. For trials that included multiple paroxetine
groups compared to placebo (e.g., comparing different dosage
Paroxetine Treatment of Anxiety and Depression
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tablets), the initial severity and change scores were combined
across groups, weighted by the respective sample sizes. All analyses
were conducted using the Comprehensive Meta Analysis 2.0
software package (Version 2.2.050, BIOSTAT, Englewood, NJ,
USA). All analyses were conducted using both random- and fixed-
effects models. Equivalent results (with regard to statistical
significance) were observed for both models in almost all analyses;
thus, the fixed-effects results are presented here. However, we have
made the results of the random-effects models available online for
interested readers (see Results S1 and Figures S1–S3). The Q [34]
and I
2 [35,36] indices were used to determine the presence or
absence of homogeneity and to assess the degree of inconsistency
between trials.
Analysis 1 evaluated the effect size magnitude when comparing
paroxetine and placebo groups in each trial, determining the
benefit of paroxetine over placebo. The effect size was calculated
as the difference in the change score between groups divided by
the pooled standard deviation. Analysis 2 determined the absolute
magnitude of change in both the placebo and paroxetine groups
for each trial (i.e., the analyses were conducted separately for each
group). This latter analysis allows us to evaluate and compare the
magnitude of change for both treatment conditions. For both
analyses, the results are presented both in raw metric (as the mean
change on the respective Hamilton rating scale) and as a
standardized pre-post mean difference (d). The standardized mean
difference results account for variation between trials in the
standard deviation of the change score [37]. Weights were
determined by the sample size times the inverse of the change
score variance. Note that in Analysis 1 the meta-analytic weights
for each study are determined by the pooled sample size and
variance across both paroxetine and placebo groups, and the
weights for Analysis 2 are determined for each group separately.
Thus, the overall effect sizes for Analysis 1 are slightly different
than the results obtained from simply subtracting the placebo from
paroxetine effect sizes in Analysis 2.
We examined several moderator variables in both analyses to
determine if study characteristics influenced the standardized
mean difference within each treatment and/or in the comparison
between paroxetine and placebo. For the HRSA, we analyzed the
following moderators: 1) Baseline severity of anxiety, as deter-
mined by the mean HRSA group score at the beginning of the
trial. No previous work has examined whether antidepressant
and/or placebo efficacy is superior in more severe cases of anxiety,
which might be predicted based on regression to the mean effects.
2) Indication (i.e., whether the individuals in the trial were treated
for panic disorder or for generalized anxiety disorder). These
analyses were designed to determine if the relative efficacy of
paroxetine in the treatment of symptoms of anxiety varied
systematically by diagnosis. 3) Length of treatment in weeks.
The double-blind trials in these analyses ranged from 8 to 12
weeks; it is possible that longer trials are associated with a larger
drug-placebo difference because the drug has more time to exert
its effects in longer trials. Although previous studies [7,38] have
not found a significant relationship between duration of treatment
and antidepressant efficacy in the treatment of depression, no
previous analyses have examined this moderator variable for
antidepressant efficacy in the treatment of anxiety. 4) Publication
status. The current database contains all trials conducted with
paroxetine, both published and unpublished; thus, publication bias
is not a concern in our outcomes. Previous work [5] has
demonstrated that the published literature may represent an
overestimate of antidepressant efficacy in the treatment of
depression, and the current analysis aimed to determine the
magnitude of publication bias in the treatment of anxiety.
For the HRSD, we analyzed the following moderators: 1)
Baseline severity of depression, as determined by the mean HRSD
group score at the beginning of each trial. Previous analyses
[7,39,40] have demonstrated that antidepressant-placebo differ-
ences increase with more severe depression. 2) Approval status
(i.e., trials submitted to the FDA for the initial approval versus
trials conducted post-approval). The 11 trials conducted following
FDA approval have not been previously included in meta-analytic
investigations. 3) Length of treatment in weeks. 4) Publication
status.
Results
Study Selection
A total of 39 trials out of the original sample of 371 studies met
inclusion criteria for the current analyses. The trial flow is
illustrated in Figure 1. Out of the excluded studies, 121 studies did
not evaluate efficacy of the drug (e.g., they evaluated the
pharmacokinetics or tolerability of the drug); 153 studies were
intervention studies that did not include a placebo group (e.g., they
compared multiple doses of the drug, compared paroxetine against
other drugs, or were open-label); 28 studies were placebo-
controlled intervention studies but did not include the HRSA or
HRSD in their outcome measures; 13 trials were extension studies
of other trials or evaluated the efficacy of paroxetine for prevention
of relapse. In nine studies, paroxetine was not the only treatment
included in the intent-to-treat samples (e.g., all participants were
previously stabilized on another treatment or received another
simultaneous treatment in addition to paroxetine or placebo).
Three studies (29060/785, 29060/251, and 29060/874) included
change scores for the HRSA but the patients had a primary
indication of depression rather than for anxiety disorders and thus
these studies were not included. However, two of these studies
(29060/251 and 29060/874) included the HRSD as an outcome
measure and were included in depression analyses. Four studies
included change scores on the HRSD, but the trials were for
individuals with obsessive-compulsive disorder (29060/116 and
29060/118) and social phobia (29060/661 and PIR104776). The
participants in these studies had low baseline severity scores (mean
HRSD scores ranging from 9 to 10) and did not appear to be
clinically depressed; thus, these studies were excluded. One study
(29060/442) met all criteria but did not include mean change
scores on the HRSD and only provided the percentage of
‘‘responders’’ (reduction by $50% on the HRSD from pre-
treatment to post-treatment) in each group. Thus, we were unable
to include this study in the meta-analysis.
Twelve studies were included for the HRSA, comprising 1,835
individuals randomized to paroxetine and 1,550 randomized to
placebo. Twenty-seven studies were included for the HRSD,
comprising 3,301 individuals randomized to paroxetine and 1,885
randomized to placebo. All studies reported their outcome
measures based on ‘‘last observation carried forward’’ methods,
meaning that the change scores for individuals who withdrew from
the study were calculated based on their final data point. This
method helps to control for selective attrition during the studies.
Study Characteristics
Information on all trials is presented in Table 1. The
corresponding publication information is provided where applica-
ble. All dosage levels were within the FDA-approved range for the
diagnosis. For the 12 trials evaluating change on the HRSA, trial
duration ranged between 8 and 12 weeks. Five trials were 8 weeks
Paroxetine Treatment of Anxiety and Depression
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were initiated between 1991 and 2003, all following FDA approval
of the medication in the treatment of depression. All trials were
conducted in adults. Seven trials evaluated panic disorder and five
trials evaluated generalized anxiety disorder. Flexible dose
adjustment was permitted in 9 of the 12 studies (i.e., the dose of
paroxetine and/or placebo could be adjusted during the trial
based on therapeutic response). Eight (67%) of the studies were
published in peer-reviewed journals.
For the 27 trials that included change on the HRSD as an
outcome measure, trial duration ranged between 4 and 12 weeks.
One trial was 4 weeks in duration, fifteen were 6 weeks, four were
8 weeks, one was 10 weeks, and six were 12 weeks. Twenty-four
trials evaluated change in adults, one trial evaluated change in
adolescents, and two trials evaluated change in the elderly.
Twenty-six trials evaluated major depressive disorder and one trial
evaluated dysthymia. Flexible dose adjustment was permitted in 21
of the 27 trials. Trials were conducted between 1982 and 2009.
The trials conducted prior to 1991 (k=16, 59% of trials) were
included as part of the original FDA submission, and an additional
11 trials (41% of trials) were conducted following FDA approval,
in 1991 or later. Sixteen (59%) of the studies were published in
peer-reviewed journals.
Mean Change on the HRSA
Table 2 displays mean baseline severity, mean change, and the
standardized mean difference (d) for each of the 12 trials reporting
change on the HRSA. Baseline HRSA data were unavailable for
two trials. Baseline severity of anxiety ranged from 18.7 to 26.0.
The mean drug-placebo difference was 2.31 (95% CI: 1.72,2.91)
points on the HRSA with a mean effect size difference of d=0.27
(95% CI: 0.20,0.33). The weighted mean change on the HRSA
was 11.11 (95% CI: 10.72,11.50) points for paroxetine and 8.77
(95% 8.35,9.20) points for placebo. The mean pre-post effect size
was d=1.23 (95% CI: 1.17,1.30) for paroxetine and d=0.96 (95%
CI: 0.90,1.02) for placebo. The differences between groups easily
met statistical significance for both the raw change scores on the
HRSA (Z=7.64, p,.001) and the standardized mean difference
(Z=7.52, p,.001). The change in the placebo group duplicated
79% of the mean change score and 78% of the standardized mean
difference in the paroxetine groups. These percentages are similar
to those found for second-generation antidepressants in the
treatment of depression [7].
A trend toward heterogeneity was observed for the mean effect
size difference between paroxetine and placebo, as demonstrated
by the indices of heterogeneity (Q(11)=17.63, p=.091, I
2=37.61
[95% CI: 12.25,55.64]). A wider range of effect sizes was observed
within each treatment group (Paroxetine: Q(11)=57.27, p,.001,
I
2=80.79 [95% CI: 74.98,85.25]; Placebo: Q(11)=65.39, p,
.001, I
2=83.18 [95% CI: 78.29,86.96]). These statistics indicate
the necessity for moderator analyses to investigate which trial
variables influenced study outcomes. Thus, we conducted mod-
erator analyses with both analytic strategies (i.e., the paroxetine-
placebo effect sizes and for paroxetine and placebo groups
separately).
HRSA Moderators
The following potential moderators were analyzed: 1) baseline
severity of anxiety; 2) indication (i.e., whether the individuals in the
trial were treated for panic disorder or for generalized anxiety
disorder); 3) length of trial in weeks; and 4) publication status.
There was no significant relationship between baseline anxiety
and the paroxetine-placebo effect size difference (Q(1)=1.58,
p=.208), as shown in Figure 2. A positive relationship was
observed between baseline anxiety on the HRSA and effect size for
both groups (Paroxetine: Q(1)=21.34, p,.001; Placebo:
Q(1)=23.51, p,.001). These latter effects are consistent with
regression to the mean artifact. Baseline severity scores were
Figure 1. Trial selection Flow chart. GSK=GlaxoSmithKline, HRSA=Hamilton Rating Scale for Anxiety, HRSD=Hamilton Rating Scale for
Depression. Please refer to the text for more specific information regarding specific exclusion criteria.
doi:10.1371/journal.pone.0106337.g001
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PLOS ONE | www.plosone.org 5 August 2014 | Volume 9 | Issue 8 | e106337unavailable for two trials (29060/187 [Panic disorder] and
BRL29060A/856 [Generalized anxiety disorder]) that were not
included in this analysis.
The effect of indication on treatment response (Table 3) was
significant. Panic disorder had a significantly larger drug-placebo
difference in terms of the standardized mean difference
(Q(1)=5.09, p=.024) and the raw change score (Q(1)=6.77,
p=.009). Mean standardized difference was d=0.36 (95% CI:
0.25,0.46) for panic disorder and d=0.20 (95% CI: 0.11,0.29) for
generalized anxiety disorder. Raw score differences were 3.24
points (95% CI: 2.32,4.15) for panic disorder and 1.64 points (95%
CI: 0.86,2.42) for generalized anxiety disorder. The effect of
indication was also significant within each group (Paroxetine:
Q(1)=24.27, p,.001; Placebo: Q(1)=32.97, p,.001). However,
the effects were opposite, with generalized anxiety disorder having
higher effect sizes and raw change scores on the HRSA for both
groups (Paroxetine: d=1.38 [95% CI: 1.29,1.46] and raw
change=11.79 [95% CI: 11.29,12.30] points; Placebo: d=1.14
[95% CI: 1.05,1.22] and raw change=10.07 [95% CI:
9.49,10.64] points) compared to panic disorder (Paroxetine:
d=1.07 [95% CI: 0.98,1.16] and raw change=10.06 [95% CI:
9.43,10.68] points; Placebo: d=0.78 [95% CI: 0.69,0.86] and raw
change=7.17 [95% CI: 6.53,7.81] points).
Longer trial lengths were significantly associated with larger
paroxetine-placebo effect sizes (Intercept=20.40, Slope=0.073
[95% CI: 0.023,0.124], Q(1)=8.02, p=.005). Within each
treatment group, trial length was inversely associated with
improvement in both groups, and appeared to have a stronger
relationship in the placebo group (Paroxetine: Intercept=2.01,
Slope=20.086 [95% CI: 20.133,20.038] Q(1)=12.51, p,.001;
Placebo: Intercept=2.04, Slope=20.116 [95% CI: 20.161,2
0.072], Q(1)=26.54, p,.001). However, this finding is difficult to
interpret because it is confounded by differences in study
indication. All five trials examining generalized anxiety disorder
had a length of eight weeks, and the seven trials examining panic
disorder were between 10 and 12 weeks. As described in the
previous paragraph, the overall change was larger in both groups
for generalized anxiety disorder, which could account for the
negative slope within each group, and the drug-placebo difference
was larger for panic disorder, which could account for the positive
slope in the difference score. Thus, we are unable to make any
firm conclusions in this analysis regarding the effect of trial length
on anxiolytic response.
There was a significant effect of publication status (Table 3),
with larger drug benefits in published trials (Q(1)=3.90, p=.048).
Published trials (k=8) had a mean drug-placebo effect size of
d=0.32 (95% CI: 0.23–0.40), and unpublished trials (k=4) had a
mean effect size of d=0.17 (95% CI: 0.06–0.29). This difference
appeared to be due to a substantially smaller placebo pre-post
effect sizes in published trials (Published: d=0.86 [95% CI:
0.79,0.94], Unpublished: d=1.15 [95% CI: 1.04,1.25],
Q(1)=18.63, p=.001). The mean pre-post effect size for the
paroxetine group was actually marginally smaller for published
compared to unpublished trials (Published: d=1.19 [95% CI:
1.12,1.27], Unpublished: d=1.32 [95% CI: 1.21,1.44],
Q(1)=3.52, p=.061).
Mean Change on the HRSD
Table 4 displays mean baseline severity, mean change, and the
standardized mean difference (d) for each of the 27 trials reporting
change on the HRSD. Baseline severity scores on the HRSD
ranged from 19.0 to 30.5 points, all in the ranges of severe to very
severe depression [41]. The weighted mean difference between
paroxetine and placebo groups across all studies was 2.51 (95%
T
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PLOS ONE | www.plosone.org 6 August 2014 | Volume 9 | Issue 8 | e106337CI: 2.06,2.96) points on the HRSD. The weighted mean effect size
difference between the two groups was 0.32 (95% CI: 0.26,0.38).
The weighted mean change on the HRSD was 11.00 (95% CI:
10.74,11.26) points for paroxetine and 8.37 (95% CI: 8.02,8.72)
points for placebo. The mean pre-post effect size was 1.39 (95%
CI: 1.34,1.44) for paroxetine, which was significantly greater
(Q(1)=87.62, p,.001) than the effect size for placebo (d=1.03
[95% CI: 0.97,1.08]). The magnitude of change in the placebo
group was equivalent to 76% of the paroxetine change scores on
the HRSD and 74% of the standardized mean difference.
Indices of heterogeneity did not indicate statistically significant
heterogeneity in the effect size difference between paroxetine and
placebo across trials (Q(26)=26.54, p=.434, I
2=2.04 [95% CI: 2
29.25,25.75]), although we did detect significant heterogeneity
within each group (Paroxetine: Q(26)=63.21, p,.001, I
2=58.87
[95% CI: 49.14–66.73]; Placebo: Q(26)=80.63, p,.001,
I
2=67.75 [95% CI: 60.63,73.59]). Nevertheless, as planned when
designing the study, moderator analyses were conducted for both
types of analyses.
HRSD Moderators
We analyzed the following moderators to determine whether
the variables could account for variance in effect size across trials:
1) baseline severity of depression; 2) approval status; 3) length of
treatment in weeks; and 4) publication status.
Figure 3 displays the relationship between baseline severity of
depression on the HRSD and treatment outcome. The benefit of
paroxetine over placebo was not significantly related to baseline
severity (Q(1)=3.01, p=.083), although there was a trend towards
a greater benefit at higher baseline severities. The predicted
paroxetine-placebo effect size at a baseline severity of HRSD=19
was d=0.20 (95% CI: 0.03,0.36) and d=0.48 (95% CI: 0.29,0.68)
at a baseline severity of HRSD=30. Greater baseline severity of
depression was associated with smaller pre-post effect sizes in both
paroxetine (Q(1)=15.45, p,.001) and placebo (Q(1)=28.23, p,
.001) groups. These effects are opposite from those expected based
on regression to the mean artifact.
A comparison of the trials submitted for the original FDA
approval (pre-approval, k=16) versus trials conducted after
approval (post-approval, k=11), shown in Table 5, revealed that
the mean paroxetine-placebo effect size did not differ significantly
as a function of approval status (Q(1)=3.27, p=.077), although
there was a trend towards a greater drug-placebo benefit in pre-
approval trials (Pre-Approval: d=0.41 [95% CI: 0.30,0.53]; Post-
Approval: d=0.29 [95% CI: 0.22,0.36]). However, we observed a
significant effect within both groups, with larger mean standard-
ized differences in the post-approval trials (Table 5). For
paroxetine, the mean effect size for pre-approval trials was
d=1.24 (95% CI: 1.15,1.33), compared to d=1.45 (95% CI:
1.39,1.50) for post-approval (Q(1)=14.43, p,.001). For placebo,
the mean effect sizes were d=0.77 (95% CI: 0.67,0.87) and
d=1.14 (95% CI: 1.07,1.21) for the pre- and post-approval trials,
respectively (Q(1)=35.01, p,.001).
An examination of the effect of trial duration on efficacy
(Figure 4) revealed that the benefit of paroxetine over placebo was
not significantly associated with trial duration (Q(1)=1.30,
p=.254). Likewise, the response to paroxetine did not significantly
differ as a function of study length (Q(1)=2.62, p=.105), although
the mean change in the placebo group was significantly larger in
longer studies (Q(1)=13.74, p,.001).
The weighted mean difference between paroxetine and placebo
was not significantly different between published and unpublished
trials (Table 5; Q(1)=1.50, p=.221). Published trials (k=16) had
a weighted mean effect size of d=0.36 (95% CI: 0.27,0.44) and
T
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PLOS ONE | www.plosone.org 7 August 2014 | Volume 9 | Issue 8 | e106337unpublished trials (k=11) had an effect size of d=0.28 (95% CI:
0.20,0.37).
Comparison of Change on the HRSA and HRSD
A comparison of the standardized mean difference between the
change on the two scales indicated that the paroxetine-placebo
effect size did not significantly differ between the HRSA and the
HRSD (HRSA: d=0.27 [95% CI: 0.20,0.33], HRSD: d=0.32
[95% CI: 0.26,0.38], Q(1)=1.41, p=.235). The mean pre-post
effect size for paroxetine treatment was significantly larger
(Q(1)=14.55, p,.001) for the HRSD (d=1.39 [95% CI:
1.34,1.44], k=27) than for the HRSA (d=1.23 [95% CI:
1.17,1.30], k=12). A non-significant trend (Q(1)=2.38, p=.123)
was observed in the placebo group for larger pre-post effect sizes
on the HRSD (d=1.03 [95% CI: 0.97,1.08]) than on the HRSA
(d=0.96 [95% CI: 0.90,1.02]).
Discussion
The current analysis is the first evaluation of the efficacy of an
SSRI medication in the treatment of multiple anxiety disorders,
and the first to utilize a complete database of published and
unpublished trials sponsored by the drug’s manufacturer. Our
results indicated that paroxetine presented a modest benefit over
placebo in the treatment of anxiety and depression, with mean
change score differences of 2.3 and 2.5 points on the HRSA and
HRSD, respectively. The standardized mean difference of
paroxetine over placebo was d=0.27 and d=0.32 for the
treatment of anxiety and depression, respectively. Put another
way, the average symptom reduction for an individual treated with
paroxetine fell at the 61
st percentile for individuals who received
placebo for anxiety, and at the 63
rd percentile for individuals who
received placebo for depression. The difference of d=0.32 in the
treatment of depression is consistent with previous meta-analyses
of antidepressant efficacy [5,7]. The mean treatment response did
Figure 2. Baseline severity of anxiety and the mean change on the Hamilton Rating Scale for Anxiety (HRSA). The size of the marker
reflects the relative weight of the study in the meta-analysis.
doi:10.1371/journal.pone.0106337.g002
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PLOS ONE | www.plosone.org 8 August 2014 | Volume 9 | Issue 8 | e106337not significantly differ between treatment of anxiety and treatment
of depression. We demonstrated that individuals given placebo
exhibited 79% of the magnitude of change compared to
paroxetine. We also provided further support for the large
magnitude of the changes in placebo groups in the treatment of
depression (76% compared to paroxetine).
Several moderator variables were significantly associated with
pre-post effect sizes for paroxetine and placebo on both the HRSA
and the HRSD. For anxiety, we found that higher baseline severity
was unrelated to drug-placebo differences, although higher
severity was associated with greater changes in both paroxetine
and placebo groups. Efficacy was superior in the treatment of
panic disorder compared to generalized anxiety disorder; however,
the overall response to both paroxetine and placebo was larger for
generalized anxiety disorder. Samples with higher baseline
severities were associated with lower changes in both paroxetine
and placebo groups in the treatment of depression, an effect that is
especially peculiar given that it is opposite to that predicted by
regression toward the mean. Longer treatment was associated with
larger pre-post placebo effect sizes in the treatment of depression.
The increase in the symptom reduction in the placebo group in
longer trials for the treatment of depression is especially
interesting, given the widespread belief that placebo effects are
short lived.
The magnitude of change in the placebo group was greater than
75% of the paroxetine response in the treatment of both anxiety
and depression. Large effect sizes in placebo groups have been
reported in the treatment of other conditions as well. However,
these changes compared to the drug effect sizes do not appear to
be as large as those observed in antidepressant trials in the
treatment of depression and anxiety. For example, a review of the
placebo effect compared to active medications (including antide-
pressants and anticonvulsants) in the treatment of pain associated
with fibromyalgia revealed that the mean change in placebo
groups accounted for 45% of the drug response [44]. This same
review found that pain reduction in the placebo groups compared
to the drug response in individuals with painful peripheral diabetic
neuropathy was 62% [44]. Similar meta-analytic reviews have
found that mean change in placebo groups replicates about 40%
of drug responses in global symptom reduction during treatment of
irritable bowel syndrome [45,46]. In a meta-analysis of change in
placebo compared to drug groups in the treatment of symptoms of
chronic fatigue syndrome, the mean placebo effect replicated only
20% of the drug response [47]. Thus, the replication of greater
than 75% of the drug response indicates that the magnitude of the
placebo effect is especially large in the treatment of anxiety and
depression.
Given the similar efficacy between paroxetine and other second-
generation antidepressants in the treatment of depression
[7,12,48], it is possible that a similar magnitude of placebo effect
sizes are present in the treatment of anxiety disorders with other
antidepressants. However, further research will be necessary to
support this proposition. The current analysis indicates that the
published literature represents an overestimate of the true efficacy
of paroxetine in the treatment of anxiety.
Although the differences between drug and placebo are
statistically significant, whether antidepressants produce clinically
significant benefits has been a topic of debate in recent years.
However, to date there has been no consensus regarding what
constitutes a clinically significant benefit. In their 2004 guidelines
for the treatment of depression, the National Institute of Health
and Clinical Excellence (NICE) proposed a mean drug-placebo
standardized mean difference (SMD) $0.50 or a difference of at
least three points on the HRSD as criteria for clinical significance
[43]. Based on these criteria, the mean antidepressant benefit in a
previous meta-analysis of trials submitted to the FDA [7] was
clinically significant only in the most severe cases of depression
(baseline HRSD $28). In a subsequent revision of their guidelines
for the treatment of depression [42], NICE replaced the term
‘‘clinical significance’’ with ‘‘clinical importance.’’ Although they
did not specify their criteria for determining whether an effect was
clinically important, their comparisons of SSRI-placebo differenc-
es in HRSD scores were the same as in the earlier guidelines, and
the same conclusions regarding ‘‘clinical importance’’ were
reached as had been reached with respect to ‘‘clinical significance’’
in 2004. Specifically, the overall difference between SSRIs and
placebo (SMD=0.34) was described as ‘‘unlikely to be of clinical
importance’’ (pg. 317). According to these criteria, the mean
Table 3. Moderator effects in trials examining change on the Hamilton Rating Scale for Anxiety.
Indication Effect Size 95% CI Q(1) p
Paroxetine - Placebo Panic 0.36 [0.25, 0.46] 5.09 .024
GAD 0.20 [0.11, 0.29]
Paroxetine Panic 1.07 [0.98, 1.16] 24.27 ,.001
GAD 1.38 [1.29, 1.46]
Placebo Panic 0.78 [0.69, 0.86] 32.97 ,.001
GAD 1.14 [1.05, 1.22]
Publication Status Effect Size 95% CI Q(1) p
Paroxetine - Placebo Published 0.32 [0.23, 0.40] 3.90 .048
Unpublished 0.17 [0.06, 0.29]
Paroxetine Published 1.19 [1.12, 1.27] 3.52 .061
Unpublished 1.32 [1.21, 1.44]
Placebo Published 0.86 [0.79, 0.94] 18.63 ,.001
Unpublished 1.15 [1.04, 1.25]
GAD=generalized anxiety disorder.
doi:10.1371/journal.pone.0106337.t003
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PLOS ONE | www.plosone.org 10 August 2014 | Volume 9 | Issue 8 | e106337difference between paroxetine and placebo in the current analyses
fell short of clinical significance for the treatment of both anxiety
and depression.
The NICE criteria have been criticized for being arbitrary and
lacking empirical justification [49]. However, a recent analysis of
raw data from 43 antidepressant trials [50] compared HRSD
change scores with clinician ratings of improvement on the
Clinical Global Impressions Scale (CGI) [51] to establish the
clinical relevance of HRSD scores. They found that change of
three points or less on the HRSD corresponded to a clinician
rating of ‘‘No Change’’ on the CGI. That is, changes of three
points or less did not correspond to a clinically detectable change
according to this clinician-rated measure. Thus, the drug-placebo
differences that have been observed in the current and previous
antidepressant meta-analyses [7,28], while statistically significant,
appear to be of marginal clinical significance.
These findings have important clinical implications. The
obvious alternative for the treatment of both anxiety and
depression is psychotherapy intervention. However, direct com-
parisons of acute phase treatment for pharmacotherapy and
psychotherapy in the treatment of major depression generally have
yielded no significant differences between the treatment modalities
[52–54]. Fewer clinical trials have directly compared antidepres-
sants and psychotherapy in the treatment of anxiety disorders,
although the available literature indicates similar comparability
between antidepressants and psychotherapy. For example, one
study [55] found that that acute phase cognitive-behavioral
therapy yields comparable efficacy to imipramine in the treatment
of panic disorder. Another study [56] found comparable 12-week
efficacy between sertraline and cognitive-behavioral therapy in the
treatment of childhood anxiety disorders. Overall, antidepressants,
psychotherapy, and placebo all yield substantial changes in
symptomatology, and are superior to no-treatment control groups
[9]. Thus, in terms of treatment, the specific type of intervention
may be less important than simply getting patients involved in
some sort of active therapy program [53].
Figure 3. Baseline severity of depression and the mean change on the Hamilton Rating Scale for Depression (HRSD). The size of the
marker reflects the relative weight of the study in the meta-analysis.
doi:10.1371/journal.pone.0106337.g003
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PLOS ONE | www.plosone.org 11 August 2014 | Volume 9 | Issue 8 | e106337When given two seemingly equivalent alternatives with regard
to symptom reduction, the decision may come down to patient
preference and to the safety profile associated with the treatment.
A meta-analysis of patient preferences when given the choice
between psychological and pharmacologic treatment [57] revealed
that 75% of patients prefer psychological intervention across 30
studies comprising individuals seeking treatment for depression or
anxiety disorders. Paroxetine and other SSRIs have also been
associated with a number of adverse events during treatment.
Greater than 70% of patients report treatment-emergent symp-
toms of sexual dysfunction including reduced desire, arousal, and/
or orgasm dysfunction, compared to less than 10% of individuals
who received placebo [58]. Other adverse reported effects include
drowsiness and weight gain, observed in greater than 7% of
patients taking SSRIs [59]. Infrequent but severe symptoms such
as serotonin syndrome [60] and increased suicidal ideation in
younger adults [61,62] have also been reported. Additionally,
abrupt withdrawal can result in a discontinuation syndrome in
66% of patients taking paroxetine, including symptoms of
dizziness, worsened mood, agitation, headache, and nausea [63].
It is also notable that the frequency of adverse events many be
underestimated in the clinical literature, as patients with depres-
sion are far more likely to self-report side effects on questionnaires
than report them to physicians as is typical during clinical trials
[64].
Although meta-analyses have indicated comparable efficacy
between antidepressants and psychotherapy during acute stage
treatment, their comparability is not as clear for long-term
treatment. One study [54] found that individuals who had
received ‘‘bona fide’’ psychotherapy from trained professionals
displayed greater symptom reduction compared to those who had
received SSRI treatment at post-acute phase follow-up ranging
from 18 to 40 weeks (d=0.29, k=6). Another meta-analysis [52]
of long-term naturalistic follow-up between individuals who were
randomized to either acute-phase pharmacotherapy or psycho-
therapy in the treatment of depression across 11 studies revealed
an advantage for psychotherapy at an average follow-up length of
15 months. Moreover, length of follow-up was a significant
moderator such that the advantage of psychotherapy over
medication was superior at longer follow-up intervals. The authors
suggest that psychotherapy offers a ‘‘prophylactic effect’’ resulting
in its long-term superiority over medications [52]. In an additional
analysis of nine studies, Imel et al. [52] demonstrated that acute-
phase discontinued psychotherapy was as efficacious as continued
pharmacotherapy at an average follow-up interval of 14 months.
That is, short-term psychotherapy (between 7 and 24 sessions)
provided an equivalent long-term benefit to continuous medica-
tion usage. These findings can help to explain why antidepressants
are frequently used for chronic treatment; more than 60% of
individuals who take antidepressants have done so for longer than
2 years, and greater than 30% use them for 5 years or more [65].
In sum, the drawbacks to antidepressant usage and their modest
benefit compared to placebo should be seriously considered before
they are chosen as the primary treatment for depression or
anxiety.
A limitation of the current work is that the trial database was
limited to studies sponsored by GlaxoSmithKline, and does not
include any additional trials that may have been conducted by
independent researchers. Additionally, it is possible that Glaxo-
SmithKline omitted some of the outcome indices from the trial
summaries posted online. A further limitation of the current
analysis is that baseline severity and change were evaluated with
the mean values for each group. An analysis including baseline
values and response at the individual patient level would afford
more power in determining a more precise estimate for the relative
benefit of paroxetine over placebo at differing levels of baseline
severity. The standard result summaries provided by the
GlaxoSmithKline Clinical Trial Register provide baseline values
and change scores only at the group level. These result summary
documents also provided limited information regarding the ways
in which the trials were conducted, which hindered our ability to
conduct a thorough analysis for study quality. However, it appears
that clinical trial sponsors are recognizing the importance of the
availability of patient-level data. Several sponsors, including
GlaxoSmithKline, have committed to posting patient-level study
results online at Clinical Study Data Request [66]. According to
Table 5. Moderator effects in trials examining change on the Hamilton Rating Scale for Depression.
Pre- vs. Post-Approval Effect Size 95% CI Q(1) p
Paroxetine - Placebo Pre-Approval 0.41 [0.30, 0.53] 3.27 .071
Post-Approval 0.29 [0.22, 0.36]
Paroxetine Pre-Approval 1.24 [1.15, 1.33] 14.43 ,.001
Post-Approval 1.45 [1.39, 1.50]
Placebo Pre-Approval 0.77 [0.67, 0.87] 35.01 ,.001
Post-Approval 1.14 [1.07, 1.21]
Publication Status Effect Size 95% CI Q(1) p
Paroxetine - Placebo Published 0.36 [0.27, 0.44] 1.50 .221
Unpublished 0.28 [0.20, 0.37]
Paroxetine Published 1.41 [1.35, 1.48] 1.45 .229
Unpublished 1.35 [1.28, 1.43]
Placebo Published 0.99 [0.91, 1.07] 1.46 .227
Unpublished 1.06 [0.98, 1.15]
Pre-approval and Post-approval refer to whether the trial was included as part of the original approval submission to the FDA (k=16) or whether it was conducted
following FDA approval in 1991 or later (k=11).
doi:10.1371/journal.pone.0106337.t005
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conducted after December 2000 freely available some time in
2015, with further studies available upon request. This site may be
a valuable resource for future meta-analyses of drug efficacy.
A recent study conducted a patient-level analysis examining the
relationship between baseline severity and antidepressant efficacy
in the treatment of depression [39]. This study analyzed
individuals from six double-blind, placebo-controlled studies of
paroxetine and imipramine and found that the drug-placebo
difference was greater than three points on the HRSD only at
baseline severity levels of 25 and above. In fact, for individuals
with mild or moderate depression (HRSD #18), the drug benefit
was less than one point on the HRSD. This finding is concerning
given that among Americans aged 12 years or older, approxi-
mately 19% and 28% of individuals with mild and moderate
depression, respectively, take antidepressants [65].
In conclusion, paroxetine provides only a modest benefit over
placebo in treating symptoms of anxiety based on the available
evidence. In addition, the current study supports previous work [7]
indicating that paroxetine treatment presents only a modest
benefit over placebo in the treatment of depression.
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marker reflects the relative weight of the study in the meta-
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significant for placebo (p=.020), but not for the difference
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Figure 4. Trial duration (in weeks) and the mean change on the Hamilton Rating Scale for Depression (HRSD). The size of the marker
reflects the relative weight of the study in the meta-analysis.
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